20 Facts About 23andMe


In 2007, 23andMe became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use.

FactSnippet No. 538,473

Investment documents from 2007 suggest that 23andMe hoped to develop a database to pursue research efforts.

FactSnippet No. 538,474

In 2012, 23andMe raised $50 million in a Series D venture round, almost doubling its capital of $52.

FactSnippet No. 538,475

In 2015, 23andMe raised $115 million in a Series E offering, increasing capital to $241 million.

FactSnippet No. 538,476

In June 2017, 23andMe created a brand marketing advertisement featuring Gru from Despicable Me.

FactSnippet No. 538,477

On July 25, 2018, 23andMe announced it a partnership with GlaxoSmithKline to allow the pharmaceutical company to use test results from 5 million customers to design new drugs.

FactSnippet No. 538,478

In January 2020, 23andMe announced it would lay off about 100 of its employees.

FactSnippet No. 538,479

In October 2021, 23andMe announced that it would acquire Lemonaid Health, a telehealth company, for $400 million with the deal closing in November.

FactSnippet No. 538,480

On December 5, 2013, 23andMe announced that it had suspended health-related genetic tests for customers who purchased the test from November 22, 2013 in order to comply with the FDA warning letter, while undergoing regulatory review.

FactSnippet No. 538,481

In May 2014, it was reported that 23andMe was exploring alternative locations abroad, including Canada, Australia, and the United Kingdom, in which to offer its full genetic testing service.

FactSnippet No. 538,482

On October 21, 2015, 23andMe announced that it would begin marketing carrier tests in the US again.

FactSnippet No. 538,483

In February 2018, 23andMe announced that its ancestry reporting would tell people what country they were from, not just what region, and increased the number of regions by 120.

FactSnippet No. 538,484

In June 2020, 23andMe published results from a study that claimed that people with type O blood may be at lower risk of catching COVID-19.

FactSnippet No. 538,485

Company collects not only genetic and personal information from customers who order DNA tests, but data about other web behavior information that 23andMe captures through the use of its website, products, software, cookies, and through its smartphone app.

FactSnippet No. 538,486

Since 23andMe is not a medical provider the company does not have to abide by standard privacy policies that must be followed at a doctor's office, such as the Health Insurance Portability and Accountability Act.

FactSnippet No. 538,487

In July 2012, 23andMe acquired the startup CureTogether, a crowdsourced treatment ratings website with data on over 600 medical conditions.

FactSnippet No. 538,488

In 2010, 23andMe said that it was able to use its database to validate work published by the NIH: identifying mutations in the gene that codes for glucocerebrosidase as a risk factor for Parkinson's disease.

FactSnippet No. 538,489

In 2015, 23andMe made a business decision to pursue drug discovery themselves, under the direction of former Genentech executive Richard Scheller.

FactSnippet No. 538,490

Also in 2016, 23andMe used self-reported data from customers to locate 17 genetic loci that seem to be associated with depression.

FactSnippet No. 538,491

Over 5 million 23andMe customers have opted in for their data being used in research.

FactSnippet No. 538,492